Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trop-1 vaccine
- Development stage
- Preclinical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Trop-1 vaccine is an experimental immunotherapeutic vaccine designed to target breast cancer. It utilizes genetically modified fibroblast cells that express the tumor-associated calcium signal transducer-1 (Trop-1) antigen, along with interleukin-2 (IL-2) and allogeneic MHC class I H-2K(b)-determinants. This vaccine aims to induce a CD8+ cell-mediated immune response against breast cancer cells, which has been shown to inhibit tumor growth and prolong survival in mouse models of breast cancer.
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on Trop-1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trop-1 vaccine.